{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T11:59:34Z","timestamp":1777636774448,"version":"3.51.4"},"reference-count":93,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","award":["-R-06814-01"],"award-info":[{"award-number":["-R-06814-01"]}],"id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1053\/j.seminhematol.2021.03.001","type":"journal-article","created":{"date-parts":[[2021,3,19]],"date-time":"2021-03-19T18:53:42Z","timestamp":1616180022000},"page":"95-102","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Management of Angioimmunoblastic T-Cell Lymphoma (AITL) and other T Follicular Helper Cell lymphomas (TFH PTCL)"],"prefix":"10.1053","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0416-5115","authenticated-orcid":false,"given":"Helen","family":"Ma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Owen A.","family":"O'Connor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrica","family":"Marchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1053\/j.seminhematol.2021.03.001_bib0001","first-page":"1113","article-title":"[Reticulosarcoma\u2013various problems concerning reticulosarcoma]","volume":"32","author":"Suchi","year":"1974","journal-title":"Nihon Rinsho"},{"issue":"7866","key":"10.1053\/j.seminhematol.2021.03.001_bib0002","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/S0140-6736(74)90553-4","article-title":"Angio-immunoblastic lymphadenopathy with dysproteinaemia","volume":"1","author":"Frizzera","year":"1974","journal-title":"Lancet"},{"issue":"1","key":"10.1053\/j.seminhematol.2021.03.001_bib0003","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJM197501022920101","article-title":"Immunoblastic lymphadenopathy. A hyperimmune entity resembling Hodgkin's disease","volume":"292","author":"Lukes","year":"1975","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2021.03.001_bib0004","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/978-3-642-81246-0_27","article-title":"Evolution of immunoblastic lymphoma in angioimmunoblastic lymphadenopathy","volume":"64","author":"Nathwani","year":"1978","journal-title":"Recent Results Cancer Res"},{"issue":"5","key":"10.1053\/j.seminhematol.2021.03.001_bib0005","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1182\/blood.V84.5.1361.1361","article-title":"A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group","volume":"84","author":"Harris","year":"1994","journal-title":"Blood"},{"issue":"20","key":"10.1053\/j.seminhematol.2021.03.001_bib0006","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"issue":"25","key":"10.1053\/j.seminhematol.2021.03.001_bib0007","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","article-title":"International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes","volume":"26","author":"Vose","year":"2008","journal-title":"J Clin Oncol"},{"issue":"5-6","key":"10.1053\/j.seminhematol.2021.03.001_bib0008","doi-asserted-by":"crossref","first-page":"545","DOI":"10.3109\/10428199909058412","article-title":"Angioimmunoblastic-like T-cell non Hodgkin's lymphoma: outcome after chemotherapy in 33 patients and review of the literature","volume":"32","author":"Pautier","year":"1999","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"10.1053\/j.seminhematol.2021.03.001_bib0009","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1200\/JCO.2011.37.3647","article-title":"Clinicopathologic characteristics of angioimmunoblastic T-cell lymphoma: analysis of the international peripheral T-cell lymphoma project","volume":"31","author":"Federico","year":"2013","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1053\/j.seminhematol.2021.03.001_bib0010","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1182\/blood.V99.2.627","article-title":"Neoplastic T cells in angioimmunoblastic T-cell lymphoma express CD10","volume":"99","author":"Attygalle","year":"2002","journal-title":"Blood"},{"issue":"11","key":"10.1053\/j.seminhematol.2021.03.001_bib0011","doi-asserted-by":"crossref","first-page":"4952","DOI":"10.1182\/blood-2006-10-055145","article-title":"The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells","volume":"109","author":"de Leval","year":"2007","journal-title":"Blood"},{"issue":"12","key":"10.1053\/j.seminhematol.2021.03.001_bib0012","doi-asserted-by":"crossref","first-page":"e505","DOI":"10.3324\/haematol.2015.133074","article-title":"A highly recurrent novel missense mutation in CD28 among angioimmunoblastic T-cell lymphoma patients","volume":"100","author":"Lee","year":"2015","journal-title":"Haematologica"},{"issue":"8","key":"10.1053\/j.seminhematol.2021.03.001_bib0013","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1038\/modpathol.3800625","article-title":"Expression of CXCL13, a chemokine highly upregulated in germinal center T-helper cells, distinguishes angioimmunoblastic T-cell lymphoma from peripheral T-cell lymphoma, unspecified","volume":"19","author":"Grogg","year":"2006","journal-title":"Mod Pathol"},{"issue":"7","key":"10.1053\/j.seminhematol.2021.03.001_bib0014","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1097\/01.pas.0000209855.28282.ce","article-title":"Programmed death-1 (PD-1) is a marker of germinal center-associated T cells and angioimmunoblastic T-cell lymphoma","volume":"30","author":"Dorfman","year":"2006","journal-title":"Am J Surg Pathol"},{"issue":"3","key":"10.1053\/j.seminhematol.2021.03.001_bib0015","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1182\/blood.V72.3.1000.bloodjournal7231000","article-title":"Clinicopathologic, immunophenotypic, and immunogenotypic analyses of immunoblastic lymphadenopathy-like T-cell lymphoma","volume":"72","author":"Tobinai","year":"1988","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2021.03.001_bib0016","article-title":"Angioimmunoblastic T-cell Lymphomas with the RHOA p.Gly17Val mutation have classic clinical and pathologic features","author":"Ondrejka","year":"2015","journal-title":"Am J Surg Pathol"},{"issue":"2","key":"10.1053\/j.seminhematol.2021.03.001_bib0017","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/sj.leu.2404013","article-title":"Identification of circulating CD10 positive T cells in angioimmunoblastic T-cell lymphoma","volume":"20","author":"Baseggio","year":"2006","journal-title":"Leukemia"},{"issue":"7","key":"10.1053\/j.seminhematol.2021.03.001_bib0018","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1038\/modpathol.2011.53","article-title":"CD10 and ICOS expression by multiparametric flow cytometry in angioimmunoblastic T-cell lymphoma","volume":"24","author":"Baseggio","year":"2011","journal-title":"Mod Pathol"},{"issue":"1","key":"10.1053\/j.seminhematol.2021.03.001_bib0019","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1002\/ijc.10758","article-title":"Angioimmunoblastic T cell lymphoma is derived from mature T-helper cells with varying expression and loss of detectable CD4","volume":"103","author":"Lee","year":"2003","journal-title":"Int J Cancer"},{"issue":"3","key":"10.1053\/j.seminhematol.2021.03.001_bib0020","doi-asserted-by":"crossref","first-page":"432","DOI":"10.3324\/haematol.2009.010991","article-title":"The inducible T-cell co-stimulator molecule is expressed on subsets of T cells and is a new marker of lymphomas of T follicular helper cell-derivation","volume":"95","author":"Marafioti","year":"2010","journal-title":"Haematologica"},{"issue":"9","key":"10.1053\/j.seminhematol.2021.03.001_bib0021","doi-asserted-by":"crossref","first-page":"4463","DOI":"10.1182\/blood-2007-08-105759","article-title":"Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials","volume":"111","author":"Mourad","year":"2008","journal-title":"Blood"},{"issue":"4","key":"10.1053\/j.seminhematol.2021.03.001_bib0022","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1182\/blood-2005-03-1083","article-title":"Angioimmunoblastic T-cell lymphoma: a neoplasm of germinal-center T-helper cells?","volume":"106","author":"Grogg","year":"2005","journal-title":"Blood"},{"issue":"6","key":"10.1053\/j.seminhematol.2021.03.001_bib0023","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1038\/modpathol.2009.12","article-title":"Angioimmunoblastic T-cell lymphoma with hyperplastic germinal centres: a neoplasia with origin in the outer zone of the germinal centre? Clinicopathological and immunohistochemical study of 10 cases with follicular T-cell markers","volume":"22","author":"Rodriguez-Justo","year":"2009","journal-title":"Mod Pathol"},{"issue":"6","key":"10.1053\/j.seminhematol.2021.03.001_bib0024","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1200\/JCO.2011.37.4223","article-title":"Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy","volume":"30","author":"Coiffier","year":"2012","journal-title":"J Clin Oncol"},{"issue":"23","key":"10.1053\/j.seminhematol.2021.03.001_bib0025","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1200\/JCO.2014.59.2782","article-title":"Belinostat in patients with relapsed or refractory peripheral T-cell lymphoma: results of the pivotal phase II BELIEF (CLN-19) study","volume":"33","author":"O'Connor","year":"2015","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1053\/j.seminhematol.2021.03.001_bib0026","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1093\/annonc\/mdv237","article-title":"Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma","volume":"26","author":"Shi","year":"2015","journal-title":"Ann Oncol"},{"issue":"19","key":"10.1053\/j.seminhematol.2021.03.001_bib0027","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1182\/blood-2013-11-536359","article-title":"Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma","volume":"123","author":"Iqbal","year":"2014","journal-title":"Blood"},{"issue":"4","key":"10.1053\/j.seminhematol.2021.03.001_bib0028","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/s11912-017-0582-9","article-title":"Genetic landscape and classification of peripheral T cell lymphomas","volume":"19","author":"Sandell","year":"2017","journal-title":"Curr Oncol Rep"},{"issue":"2","key":"10.1053\/j.seminhematol.2021.03.001_bib0029","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/ng.2873","article-title":"Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas","volume":"46","author":"Palomero","year":"2014","journal-title":"Nat Genet"},{"issue":"12","key":"10.1053\/j.seminhematol.2021.03.001_bib0030","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1038\/ng.3442","article-title":"The mutational landscape of cutaneous T cell lymphoma and sezary syndrome","volume":"47","author":"da Silva Almeida","year":"2015","journal-title":"Nat Genet"},{"issue":"4","key":"10.1053\/j.seminhematol.2021.03.001_bib0031","doi-asserted-by":"crossref","first-page":"679","DOI":"10.3324\/haematol.2017.182444","article-title":"Histone modifier gene mutations in peripheral T-cell lymphoma not otherwise specified","volume":"103","author":"Ji","year":"2018","journal-title":"Haematologica"},{"issue":"14","key":"10.1053\/j.seminhematol.2021.03.001_bib0032","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1182\/blood-2018-01-824607","article-title":"North American ATLL has a distinct mutational and transcriptional profile and responds to epigenetic therapies","volume":"132","author":"Shah","year":"2018","journal-title":"Blood"},{"issue":"8","key":"10.1053\/j.seminhematol.2021.03.001_bib0033","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1182\/blood-2011-11-391748","article-title":"IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma","volume":"119","author":"Cairns","year":"2012","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.seminhematol.2021.03.001_bib0034","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1056\/NEJMc1111708","article-title":"TET2 and DNMT3A mutations in human T-cell lymphoma","volume":"366","author":"Couronne","year":"2012","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1053\/j.seminhematol.2021.03.001_bib0035","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1182\/blood-2013-10-531509","article-title":"A targeted mutational landscape of angioimmunoblastic T-cell lymphoma","volume":"123","author":"Odejide","year":"2014","journal-title":"Blood"},{"issue":"2","key":"10.1053\/j.seminhematol.2021.03.001_bib0036","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/ng.2872","article-title":"Somatic RHOA mutation in angioimmunoblastic T cell lymphoma","volume":"46","author":"Sakata-Yanagimoto","year":"2014","journal-title":"Nat Genet"},{"issue":"5897","key":"10.1053\/j.seminhematol.2021.03.001_bib0037","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1126\/science.1164382","article-title":"An integrated genomic analysis of human glioblastoma multiforme","volume":"321","author":"Parsons","year":"2008","journal-title":"Science"},{"issue":"7347","key":"10.1053\/j.seminhematol.2021.03.001_bib0038","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/nature10066","article-title":"TET1 and hydroxymethylcytosine in transcription and DNA methylation fidelity","volume":"473","author":"Williams","year":"2011","journal-title":"Nature"},{"issue":"6","key":"10.1053\/j.seminhematol.2021.03.001_bib0039","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/s12276-019-0230-6","article-title":"The cancer driver genes IDH1\/2, JARID1C\/KDM5C, and UTX\/ KDM6A: crosstalk between histone demethylation and hypoxic reprogramming in cancer metabolism","volume":"51","author":"Chang","year":"2019","journal-title":"Experimental & molecular med"},{"issue":"7","key":"10.1053\/j.seminhematol.2021.03.001_bib0040","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1182\/blood.V79.7.1789.1789","article-title":"Detection and localization of Epstein-Barr viral genomes in angioimmunoblastic lymphadenopathy and angioimmunoblastic lymphadenopathy-like lymphoma","volume":"79","author":"Weiss","year":"1992","journal-title":"Blood"},{"issue":"4","key":"10.1053\/j.seminhematol.2021.03.001_bib0041","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1111\/j.1365-2141.1990.tb07807.x","article-title":"Detection of Epstein-Barr virus DNA by polymerase chain reaction in lymph node biopsies from patients with angioimmunoblastic lymphadenopathy","volume":"75","author":"Knecht","year":"1990","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1053\/j.seminhematol.2021.03.001_bib0042","doi-asserted-by":"crossref","first-page":"610","DOI":"10.3390\/cancers13040610","article-title":"Comprehensive Epstein-Barr Virus Transcriptome by RNA-Sequencing in Angioimmunoblastic T Cell Lymphoma (AITL) and Other Lymphomas","volume":"13","author":"Bayda","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"10","key":"10.1053\/j.seminhematol.2021.03.001_bib0043","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1038\/sj.leu.2402642","article-title":"Angio-immunoblastic T cell lymphoma (AILD-TL) rich in large B cells and associated with Epstein-Barr virus infection. A different subtype of AILD-TL?","volume":"16","author":"Lome-Maldonado","year":"2002","journal-title":"Leukemia"},{"issue":"4","key":"10.1053\/j.seminhematol.2021.03.001_bib0044","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1002\/ijc.2910510410","article-title":"Prevalence of Epstein-Barr virus DNA in different T-cell lymphoma entities in a European population","volume":"51","author":"Ott","year":"1992","journal-title":"Int J Cancer"},{"issue":"8902","key":"10.1053\/j.seminhematol.2021.03.001_bib0045","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/S0140-6736(94)90045-0","article-title":"Epstein-Barr virus, B cells, T cells, and a lymphoproliferative disorder","volume":"343","author":"Ott","year":"1994","journal-title":"Lancet"},{"issue":"10","key":"10.1053\/j.seminhematol.2021.03.001_bib0046","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1080\/10428190701593628","article-title":"Angioimmunoblastic T-cell lymphoma with an evolving Epstein Barr virus-positive diffuse large B-cell lymphoma with unusual clinical and pathologic findings","volume":"48","author":"Maegawa","year":"2007","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"10.1053\/j.seminhematol.2021.03.001_bib0047","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0925-5710(98)00005-X","article-title":"Development of Epstein-Barr virus-associated B cell lymphoma after intensive treatment of patients with angioimmunoblastic lymphadenopathy with dysproteinemia","volume":"67","author":"Matsue","year":"1998","journal-title":"Int J Hematol"},{"issue":"1","key":"10.1053\/j.seminhematol.2021.03.001_bib0048","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1182\/blood.V82.1.241.bloodjournal821241","article-title":"B-cell lymphoma after angioimmunoblastic lymphadenopathy: a case with oligoclonal gene rearrangements associated with Epstein-Barr virus","volume":"82","author":"Abruzzo","year":"1993","journal-title":"Blood"},{"issue":"3","key":"10.1053\/j.seminhematol.2021.03.001_bib0049","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1309\/6UTX-GVC0-12ND-JJEU","article-title":"Epstein-Barr virus-associated B-cell lymphoproliferative disorders in angloimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma, unspecified","volume":"117","author":"Zettl","year":"2002","journal-title":"Am J Clin Pathol"},{"issue":"1","key":"10.1053\/j.seminhematol.2021.03.001_bib0050","doi-asserted-by":"crossref","first-page":"30","DOI":"10.3904\/kjim.2008.23.1.30","article-title":"Epstein-Barr virus-positivity in tumor has no correlation with the clinical outcomes of patients with angioimmunoblastic T-cell lymphoma","volume":"23","author":"Lee","year":"2008","journal-title":"Korean J Intern Med"},{"issue":"2","key":"10.1053\/j.seminhematol.2021.03.001_bib0051","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1002\/cam4.2742","article-title":"EBV status has prognostic implication among young patients with angioimmunoblastic T-cell lymphoma","volume":"9","author":"Eladl","year":"2020","journal-title":"Cancer Med"},{"issue":"10","key":"10.1053\/j.seminhematol.2021.03.001_bib0052","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.3324\/haematol.2011.061507","article-title":"Targeting intratumoral B cells with rituximab in addition to CHOP in angioimmunoblastic T-cell lymphoma. A clinicobiological study of the GELA","volume":"97","author":"Delfau-Larue","year":"2012","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2021.03.001_bib0053","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJM199304083281404","article-title":"Comparison of a Standard Regimen (CHOP) with three intensive chemotherapy regimens for advanced Non-Hodgkin's lymphoma","volume":"328","author":"Fisher","year":"1993","journal-title":"New England Journal of Medicine"},{"issue":"11","key":"10.1053\/j.seminhematol.2021.03.001_bib0054","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1093\/annonc\/mdu443","article-title":"Peripheral T-cell lymphomas in a large US multicenter cohort: prognostication in the modern era including impact of frontline therapy","volume":"25","author":"Abramson","year":"2014","journal-title":"Annals of oncology: official journal of the European Society for Medical Oncology"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2021.03.001_bib0055","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1182\/blood-2020-134440","article-title":"Final Analysis of the Ro-CHOP Phase III Study (Conducted by LYSA): romidepsin Plus CHOP in patients with peripheral T-Cell lymphoma","volume":"136","author":"Bachy","year":"2020","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2021.03.001_bib0056","article-title":"Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial","author":"Horwitz","year":"2018","journal-title":"Lancet"},{"issue":"16","key":"10.1053\/j.seminhematol.2021.03.001_bib0057","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1200\/JCO.2012.44.7524","article-title":"Survival of patients with peripheral T-Cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors","volume":"31","author":"Mak","year":"2013","journal-title":"Journal of Clinical Oncology"},{"issue":"5","key":"10.1053\/j.seminhematol.2021.03.001_bib0058","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1111\/bjh.14477","article-title":"The survival outcome of patients with relapsed\/refractory peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma","volume":"176","author":"Chihara","year":"2017","journal-title":"British Journal of Haematology"},{"issue":"1","key":"10.1053\/j.seminhematol.2021.03.001_bib0059","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/hon.2705","article-title":"Survival benefit in patients with peripheral T-cell lymphomas after treatments with novel therapies and clinical trials","volume":"38","author":"Ma","year":"2020","journal-title":"Hematological Oncology"},{"issue":"6","key":"10.1053\/j.seminhematol.2021.03.001_bib0060","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1002\/ajh.25463","article-title":"Single agents vs combination chemotherapy in relapsed and refractory peripheral T-cell lymphoma: Results from the comprehensive oncology measures for peripheral T-cell lymphoma treatment (COMPLETE) registry","volume":"94","author":"Stuver","year":"2019","journal-title":"American Journal of Hematology"},{"issue":"6","key":"10.1053\/j.seminhematol.2021.03.001_bib0061","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1080\/1042819031000077124","article-title":"Activity of a novel anti-folate (PDX, 10-propargyl 10-deazaaminopterin) against human lymphoma is superior to methotrexate and correlates with tumor RFC-1 gene expression","volume":"44","author":"Wang","year":"2003","journal-title":"Leuk Lymphoma"},{"issue":"9","key":"10.1053\/j.seminhematol.2021.03.001_bib0062","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1200\/JCO.2010.29.9024","article-title":"Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study","volume":"29","author":"O'Connor","year":"2011","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1053\/j.seminhematol.2021.03.001_bib0063","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1111\/bjh.14477","article-title":"The survival outcome of patients with relapsed\/refractory peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma","volume":"176","author":"Chihara","year":"2017","journal-title":"Br J Haematol"},{"issue":"9","key":"10.1053\/j.seminhematol.2021.03.001_bib0064","first-page":"2145","article-title":"Efficacy and safety of single-agent pralatrexate for treatment of angioimmunoblastic T-cell lymphoma after failure of first line therapy: a pooled analysis","volume":"61","author":"Zhu","year":"2020","journal-title":"null"},{"key":"10.1053\/j.seminhematol.2021.03.001_bib0065","doi-asserted-by":"crossref","first-page":"2910","DOI":"10.1182\/blood-2018-99-119684","article-title":"Management of Mucositis with the Use of Leucovorin As Adjunct to Pralatrexate in Treatment of Peripheral T-Cell Lymphomas (PTCL) \u2014 Results from a Prospective Multicenter Phase 2 Clinical Trial","volume":"132","author":"Shustov","year":"2018","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2021.03.001_bib0066","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s13045-016-0243-8","article-title":"Romidepsin for the treatment of relapsed\/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial","volume":"9","author":"Foss","year":"2016","journal-title":"J Hematol Oncol"},{"issue":"1","key":"10.1053\/j.seminhematol.2021.03.001_bib0067","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/s13045-017-0518-8","article-title":"Erratum to: romidepsin for the treatment of relapsed\/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial","volume":"10","author":"Foss","year":"2017","journal-title":"J Hematol Oncol"},{"issue":"4","key":"10.1053\/j.seminhematol.2021.03.001_bib0068","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1002\/hon.2320","article-title":"Romidepsin induces durable responses in patients with relapsed or refractory angioimmunoblastic T-cell lymphoma","volume":"35","author":"Pro","year":"2017","journal-title":"Hematol Oncol"},{"issue":"8","key":"10.1053\/j.seminhematol.2021.03.001_bib0069","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1080\/10428194.2020.1753044","article-title":"Characterizing the belinostat response in patients with relapsed or refractory angioimmunoblastic T-cell lymphoma","volume":"61","author":"Sawas","year":"2020","journal-title":"Leukemia Lymphoma"},{"issue":"19","key":"10.1053\/j.seminhematol.2021.03.001_bib0070","doi-asserted-by":"crossref","first-page":"4640","DOI":"10.1182\/bloodadvances.2020002396","article-title":"T follicular helper phenotype predicts response to histone deacetylase inhibitors in relapsed\/refractory peripheral T-cell lymphoma","volume":"4","author":"Ghione","year":"2020","journal-title":"Blood Advances"},{"issue":"20","key":"10.1053\/j.seminhematol.2021.03.001_bib0071","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1182\/blood-2013-12-542142","article-title":"Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin","volume":"123","author":"Horwitz","year":"2014","journal-title":"Blood"},{"issue":"8","key":"10.1053\/j.seminhematol.2021.03.001_bib0072","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.3324\/haematol.2013.084913","article-title":"CD30 expression in peripheral T-cell lymphomas","volume":"98","author":"Sabattini","year":"2013","journal-title":"Haematologica"},{"issue":"19","key":"10.1053\/j.seminhematol.2021.03.001_bib0073","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1182\/blood-2014-07-584953","article-title":"Immunohistochemistry as a valuable tool to assess CD30 expression in peripheral T-cell lymphomas: high correlation with mRNA levels","volume":"124","author":"Bossard","year":"2014","journal-title":"Blood"},{"issue":"8","key":"10.1053\/j.seminhematol.2021.03.001_bib0074","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1182\/blood-2017-08-802470","article-title":"Activity of the PI3K-delta,gamma inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma","volume":"131","author":"Horwitz","year":"2018","journal-title":"Blood"},{"issue":"8","key":"10.1053\/j.seminhematol.2021.03.001_bib0075","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1200\/JCO.18.00899","article-title":"Randomized phase III study of Alisertib or investigator's choice (Selected Single Agent) in patients with relapsed or refractory peripheral T-Cell lymphoma","volume":"37","author":"O'Connor","year":"2019","journal-title":"Journal of Clinical Oncology"},{"issue":"6","key":"10.1053\/j.seminhematol.2021.03.001_bib0076","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.clml.2019.03.022","article-title":"Phase II study of the PD-1 Inhibitor pembrolizumab for the treatment of relapsed or refractory mature T-cell lymphoma","volume":"19","author":"Barta","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"Supplement_1","key":"10.1053\/j.seminhematol.2021.03.001_bib0077","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1182\/blood-2019-126194","article-title":"A phase II study of nivolumab in patients with relapsed or refractory peripheral T-Cell lymphoma","volume":"134","author":"Bennani","year":"2019","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2021.03.001_bib0078","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1182\/blood-2020-136465","article-title":"A Phase I Study of Anti-ICOS Antibody MEDI-570 for Relapsed\/Refractory (R\/R) Peripheral T-Cell Lymphoma (PTCL) and Angioimmunoblastic T-Cell Lymphoma (AITL) (NCI-9930)","volume":"136","author":"Chavez","year":"2020","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2021.03.001_bib0079","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.31861","article-title":"The role of autologous stem cell transplantation in patients with nodal peripheral T-cell lymphomas in first complete remission: Report from COMPLETE, a prospective, multicenter cohort study","author":"Park","year":"2019","journal-title":"Cancer"},{"issue":"12","key":"10.1053\/j.seminhematol.2021.03.001_bib0080","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.1182\/blood-2011-08-374371","article-title":"Retrospective analysis of prognostic factors for angioimmunoblastic T-cell lymphoma: a multicenter cooperative study in Japan","volume":"119","author":"Tokunaga","year":"2012","journal-title":"Blood"},{"issue":"24","key":"10.1053\/j.seminhematol.2021.03.001_bib0081","doi-asserted-by":"crossref","first-page":"3951","DOI":"10.1200\/JCO.2008.20.4628","article-title":"Allogeneic stem cell transplantation is able to induce long-term remissions in angioimmunoblastic T-Cell Lymphoma: a retrospective study from the lymphoma working party of the european group for blood and marrow transplantation","volume":"27","author":"Kyriakou","year":"2009","journal-title":"Journal of Clinical Oncology"},{"issue":"22","key":"10.1053\/j.seminhematol.2021.03.001_bib0082","doi-asserted-by":"crossref","first-page":"4164","DOI":"10.1182\/blood.V128.22.4164.4164","article-title":"Treatment with Hypomethylating Agent 5-Azacytidine induces sustained response in angioimmunoblastic T Cell lymphomas","volume":"128","author":"Delarue","year":"2016","journal-title":"Blood"},{"issue":"2","key":"10.1053\/j.seminhematol.2021.03.001_bib0083","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/bjh.13566","article-title":"The combination of hypomethylating agents and histone deacetylase inhibitors produce marked synergy in preclinical models of T-cell lymphoma","volume":"171","author":"Marchi","year":"2015","journal-title":"Br J Haematol"},{"issue":"9","key":"10.1053\/j.seminhematol.2021.03.001_bib0084","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1158\/1078-0432.CCR-14-2249","article-title":"Preclinical pharmacologic evaluation of pralatrexate and romidepsin confirms potent synergy of the combination in a murine model of human T-cell lymphoma","volume":"21","author":"Jain","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2021.03.001_bib0085","first-page":"2743","article-title":"Azacytidine and decitabine exhibit differential effects on cytotoxicity and methylation and exhibit class synergy with hdaci in models of Ptcl","volume":"130","author":"Scotto","year":"2017","journal-title":"Blood"},{"issue":"4","key":"10.1053\/j.seminhematol.2021.03.001_bib0086","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1182\/blood-2017-09-806737","article-title":"A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma","volume":"131","author":"Amengual","year":"2018","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2021.03.001_bib0087","article-title":"Combined Oral 5-Azacytidine and Romidepsin are Highly Effective in Patients with PTCL: A Multicenter Phase 2 Study","author":"Falchi","year":"2020","journal-title":"Blood"},{"issue":"14","key":"10.1053\/j.seminhematol.2021.03.001_bib0088","doi-asserted-by":"crossref","first-page":"3648","DOI":"10.1158\/1078-0432.CCR-10-0671","article-title":"Pralatrexate is synergistic with the proteasome inhibitor bortezomib in in vitro and in vivo models of T-cell lymphoid malignancies","volume":"16","author":"Marchi","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1053\/j.seminhematol.2021.03.001_bib0089","doi-asserted-by":"crossref","first-page":"e326","DOI":"10.1016\/S2352-3026(15)00097-6","article-title":"Panobinostat in combination with bortezomib in patients with relapsed or refractory peripheral T-cell lymphoma: an open-label, multicentre phase 2 trial","volume":"2","author":"Tan","year":"2015","journal-title":"Lancet Haematol"},{"issue":"7","key":"10.1053\/j.seminhematol.2021.03.001_bib0090","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.3346\/jkms.2016.31.7.1160","article-title":"Pralatrexate in Combination with Bortezomib for Relapsed or Refractory Peripheral T Cell Lymphoma in 5 Elderly Patients","volume":"31","author":"Lee","year":"2016","journal-title":"J Korean Med Sci"},{"issue":"16 Supplement","key":"10.1053\/j.seminhematol.2021.03.001_bib0091","article-title":"Abstract CT160: the integration of PD1 blockade with epigenetic therapy is highly active and safe in heavily treated patients with T-cell lymphoma","volume":"80","author":"Marchi","year":"2020","journal-title":"Cancer Research"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2021.03.001_bib0092","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1182\/blood-2020-143252","article-title":"A phase II study of pembrolizumab in combination with romidepsin demonstrates durable responses in relapsed or refractory T-Cell Lymphoma (TCL)","volume":"136","author":"Iyer","year":"2020","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2021.03.001_bib0093","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1182\/blood-2020-136023","article-title":"Multi-Center Phase II Study of Oral Azacitidine (CC-486) Plus CHOP As Initial Treatment for Peripheral T-Cell Lymphoma (PTCL)","volume":"136","author":"Ruan","year":"2020","journal-title":"Blood"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196321000172?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196321000172?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T05:53:39Z","timestamp":1777442019000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0037196321000172"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":93,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["S0037196321000172"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2021.03.001","relation":{},"ISSN":["0037-1963"],"issn-type":[{"value":"0037-1963","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of Angioimmunoblastic T-Cell Lymphoma (AITL) and other T Follicular Helper Cell lymphomas (TFH PTCL)","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2021.03.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}